Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Dermatol Clin ; 42(3): 377-386, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38796269

ABSTRACT

Pediatric psoriasis is a chronic inflammatory skin condition. Current treatment modalities include topical medications, phototherapy, and systemic drugs, including biological agents. In cases of moderate-to-severe psoriasis recalcitrant to other therapies, biological therapies are often an attractive option given their dosing schedules, safety profiles, and need for less frequent laboratory monitoring, when compared with traditional systemic therapies. This article reviews biological treatment options approved for pediatric psoriasis and identifies others actively under investigation.


Subject(s)
Adalimumab , Biological Products , Dermatologic Agents , Psoriasis , Ustekinumab , Humans , Psoriasis/drug therapy , Psoriasis/therapy , Child , Adalimumab/therapeutic use , Biological Products/therapeutic use , Ustekinumab/therapeutic use , Dermatologic Agents/therapeutic use , Biological Therapy , Infliximab/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Etanercept/therapeutic use , Antibodies, Monoclonal/therapeutic use , Rituximab/therapeutic use , Interleukin 1 Receptor Antagonist Protein/therapeutic use , Alefacept , Certolizumab Pegol/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...